N. Kentepozidis

发表

Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study.

S. Kakkos, I. Boukovinas, H. Kalofonos, 2020, International angiology : a journal of the International Union of Angiology.

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

I. Boukovinas, N. Ziras, V. Georgoulias, 2017, British Journal of Cancer.

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG)

I. Boukovinas, N. Malamos, N. Ziras, 2014, Breast Cancer Research and Treatment.

Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

S. Agelaki, V. Georgoulias, I. Boukovinas, 2010 .

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

V. Georgoulias, I. Boukovinas, N. Malamos, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The case of the missed chest radiograph: bilateral mammary gland metastases mimicking multifocal primary breast cancer as the initial manifestation of non-small-cell lung cancer.

G. Mountzios, N. Kentepozidis, Anastasios Gyftopoulos, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Dose Escalation Study of the Biweekly Administration of Paclitaxel, Oxaliplatin and Capecitabine in Patients with Advanced Solid Tumors

D. Mavroudis, V. Georgoulias, A. Kalykaki, 2007, Oncology.

Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

V. Georgoulias, I. Boukovinas, N. Ziras, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer

V. Georgoulias, J. Souglakos, A. Matikas, 2019, Targeted oncology.

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

V. Georgoulias, A. Voutsina, S. Agelaki, 2012, Clinical lung cancer.

Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.

V. Georgoulias, M. Plataki, E. Samantas, 2017, Lung cancer.

Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.

V. Georgoulias, A. Kalykaki, A. Polyzos, 2010, Lung cancer.

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study

V. Georgoulias, A. Soultati, A. Kalykaki, 2012, Cancer Chemotherapy and Pharmacology.

Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients

V. Georgoulias, F. Koinis, A. Kotsakis, 2016, Scientific Reports.

Phase I Study of Weekly Docetaxel and Liposomal Doxorubicin in Patients with Advanced Solid Tumors

V. Georgoulias, A. Kalykaki, L. Vamvakas, 2005, Oncology.

Leprosy Reactivation and Lepromatous Gangrene Associated with Chemotherapy for Advanced Gastric Cancer: A Case Report and Review of the Literature -

N. Kentepozidis, M. Bakogeorgos, C. Tsironis, 2011 .

A Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors

S. Agelaki, M. Ignatiadis, V. Georgoulias, 2007, Oncology.

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer

R. Tell, T. Guren, G. Carlsson, 2022, ESMO open.

ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer.

V. Georgoulias, T. Guren, G. Carlsson, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

K. Syrigos, V. Georgoulias, H. Gogas, 2021, Cancer Immunology, Immunotherapy.

Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group

S. Agelaki, V. Georgoulias, D. Mavroudis, 2016 .

In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii.

E. Giamarellos‐Bourboulis, D. Plachouras, H. Giamarellou, 2007, Diagnostic microbiology and infectious disease.

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

I. Boukovinas, N. Ziras, J. Souglakos, 2012, British Journal of Cancer.

Small cell carcinoma of the stomach: A report of two cases and a review of the literature

V. Georgoulias, D. Kalkanis, A. Kotsakis, 2018, Molecular and clinical oncology.

Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer.

V. Georgoulias, A. Matikas, A. Kotsakis, 2016, Clinical lung cancer.

A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.

D. Mavroudis, V. Georgoulias, E. Papadimitraki, 2014, Lung cancer.

Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.

V. Georgoulias, J. Syrios, A. Polyzos, 2019, Minerva ginecologica.

Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study

S. Agelaki, D. Mavroudis, V. Georgoulias, 2006, Cancer Chemotherapy and Pharmacology.

Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa.

T. Tsaganos, E. Giamarellos‐Bourboulis, D. Plachouras, 2005, Diagnostic microbiology and infectious disease.

Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer

S. Giannouli, H. Gogas, A. Psyrri, 2019, AntiCancer Research.

Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group

V. Georgoulias, I. Boukovinas, N. Ziras, 2022, Current oncology.

Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial

M. Dimopoulos, G. Lazaridis, A. Psyrri, 2020, British Journal of Cancer.

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group

V. Georgoulias, I. Boukovinas, P. Economopoulou, 2018, Annals of gastroenterology.

Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

V. Georgoulias, E. Stathopoulos, J. Souglakos, 2014, Cancer Chemotherapy and Pharmacology.

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy

E. Terpos, M. Gkotzamanidou, N. Kentepozidis, 2021, International journal of molecular sciences.

A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract

V. Georgoulias, N. Ziras, N. Karachaliou, 2010, Oncology.

Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First‐Line Treatment of Metastatic Triple‐Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group

D. Mavroudis, V. Georgoulias, E. Saloustros, 2017, Clinical breast cancer.

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group

V. Georgoulias, G. Fountzilas, S. Agelaki, 2017, British Journal of Cancer.

A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer.

V. Georgoulias, K. Syrigos, N. Tzanakis, 2004, Lung cancer.

Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial

A. Chella, C. Gridelli, V. Georgoulias, 2020, British Journal of Cancer.

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

S. Agelaki, V. Georgoulias, N. Karachaliou, 2015, Cancer Chemotherapy and Pharmacology.

Metronomic Chemotherapy in Non-Small-Cell Lung Cancer

V. Georgoulias, A. Kotsakis, N. Kentepozidis, 2014 .

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomiz

S. Agelaki, V. Georgoulias, D. Mavroudis, 2015, Lung cancer.

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group

V. Georgoulias, S. Agelaki, I. Varthalitis, 2013, Journal of chemotherapy.

A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

V. Georgoulias, A. Pallis, A. Kotsakis, 2006, Lung cancer.

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

F. Fostira, C. Papadimitriou, G. Aravantinos, 2021, Cancers.

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)

V. Georgoulias, P. Economopoulou, A. Polyzos, 2017, Clinical and Translational Oncology.

Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.

V. Georgoulias, A. Polyzos, A. Kotsakis, 2017, Journal of geriatric oncology.

Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab

D. Mavroudis, V. Georgoulias, A. Kalykaki, 2011, Cancer Chemotherapy and Pharmacology.

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer

S. Agelaki, V. Georgoulias, I. Boukovinas, 2014, Cancer Chemotherapy and Pharmacology.

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

V. Georgoulias, I. Boukovinas, N. Malamos, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer therapy and cardiovascular risk: focus on bevacizumab

P. Economopoulou, A. Kotsakis, N. Kentepozidis, 2015, Cancer management and research.

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

S. Agelaki, V. Georgoulias, K. Syrigos, 2010, BMC Cancer.

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.

V. Georgoulias, M. Ignatiadis, I. Boukovinas, 2005, Lung cancer.

Adrenal Incidentalomas in Cancer Patients Are Not Always “Innocent”: A Case Report and Review of the Literature

E. Patsouris, P. Economopoulou, G. Mountzios, 2013, Case reports in medicine.

Extensive cutaneous metastases of pancreatic adenocarcinoma: a case report and review of the literature

P. Economopoulou, I. Kotsantis, N. Kentepozidis, 2016, Clinical case reports.

Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.

V. Georgoulias, G. Rigas, A. Polyzos, 2016, Clinical lung cancer.

Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece.

M. Dimopoulos, P. Economopoulou, G. Mountzios, 2015, Journal of geriatric oncology.

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.

K. Syrigos, V. Georgoulias, K. Syrigos, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.

V. Georgoulias, A. Pallis, N. Vardakis, 2011, Clinical lung cancer.

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours

S. Agelaki, V. Georgoulias, M. Marselos, 2007, British Journal of Cancer.

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group

S. Agelaki, V. Georgoulias, A. Soultati, 2013, Cancer Chemotherapy and Pharmacology.

Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 “MELPOMENI” study)

C. Papadimitriou, I. Boukovinas, V. Michalaki, 2022, AntiCancer Research.

Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group

V. Georgoulias, I. Boukovinas, J. Souglakos, 2017, Annals of gastroenterology.

Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG).

V. Georgoulias, N. Ziras, J. Souglakos, 2019, Journal of geriatric oncology.

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

V. Georgoulias, D. Mavroudis, I. Varthalitis, 2016, British Journal of Cancer.

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

K. Syrigos, S. Agelaki, V. Georgoulias, 2016, Cancer Chemotherapy and Pharmacology.

Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial

D. Mavroudis, V. Georgoulias, A. Polyzos, 2011, Cancer Chemotherapy and Pharmacology.

Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients

A. Psyrri, D. Daliani, G. Mountzios, 2023, Oral.

Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)

M. Dimopoulos, A. Papatsoris, G. Aravantinos, 2018, Expert review of pharmacoeconomics & outcomes research.

Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience

S. Agelaki, V. Georgoulias, I. Boukovinas, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Continuous Administration of Daily Low-Dose Temozolomide in Pretreated Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study

V. Georgoulias, A. Kalykaki, N. Vardakis, 2009, Oncology.

AMALTHEA: Prospective, Single‐Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First‐Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer

G. Aravantinos, C. Petraki, G. Fountzilas, 2018, Clinical colorectal cancer.

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer

S. Agelaki, D. Mavroudis, V. Georgoulias, 2011, Cancer Chemotherapy and Pharmacology.

Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: a single institution comparative study.

P. Economopoulou, G. Mountzios, N. Kentepozidis, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Cancer Management and Research Dovepress Cancer Therapy and Cardiovascular Risk: Focus on Bevacizumab

P. Economopoulou, A. Kotsakis, N. Kentepozidis, 2022 .

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .